

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:664Serial No.
09/599,152

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E.
Edmund Kim

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 2Other Art
See Page 2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
25	A14	2001/0034363	10/25/01	Li <i>et al.</i>	514	449	3/30/98
	A15	2001/0041189	11/15/01	Xu	424	488	4/13/99
	A16	4,418,068	11/29/83	Jones	424	267	12/16/81
	A17	4,507,466	3/26/85	Tomalia <i>et al.</i>	528	332	1/07/83
	A18	4,558,120	12/10/85	Tomalia <i>et al.</i>	528	363	12/27/83
	A19	4,568,737	2/04/86	Tomalia <i>et al.</i>	528	332	8/17/84
	A20	4,587,329	5/06/86	Tomalia <i>et al.</i>	528	363	7/19/85
	A21	4,631,337	12/23/86	Tomalia <i>et al.</i>	528	391	7/115/85
	A22	4,694,064	9/15/87	Tomalia <i>et al.</i>	528	332	2/28/86
	A23	4,713,975	12/22/87	Tomalia <i>et al.</i>	73	864.8	5/30/86
	A24	4,732,863	3/22/88	Tomasi <i>et al.</i>	436	547	12/31/84
	A25	4,737,550	4/12/88	Tomalia	525	419	12/08/86
	A26	4,857,599	8/15/89	Tomalia <i>et al.</i>	525	259	2/08/88
	A27	4,871,779	10/03/89	Killat <i>et al.</i>	521	28	12/23/85
	A28	5,087,616	2/11/92	Myers <i>et al.</i>	514	21	8/06/87
	A29	5,164,294	11/17/92	Skold <i>et al.</i>	435	7.5	7/07/89
	A30	5,412,072	5/02/95	Sakurai <i>et al.</i>	530	322	3/21/90
	A31	5,534,241	7/09/96	Torchilin <i>et al.</i>	424	9.321	7/23/93
	A32	5,605,671	2/25/97	Lyle <i>et al.</i>	424	1.41	4/29/94
	A33	5,635,603	6/03/97	Hansen <i>et al.</i>	530	391.5	12/05/94
	A34	5,670,132	9/23/97	Griffiths <i>et al.</i>	424	1.11	9/20/94
	A35	5,830,431	11/03/98	Srinivasan <i>et al.</i>	424	1.69	6/07/95
	A36	5,908,777	6/01/99	Lee <i>et al.</i>	435	320.1	3/23/95

25387887/1

EXAMINER: Jones

DATE CONSIDERED: 6/15/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E.
Edmund Kim

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A37	5,977,163	11/02/99	Li <i>et al.</i>	514	449	3/11/97
	A38	6,071,533	6/06/00	Papahadjopoulos <i>et al.</i>	424	450	11/17/95
	A39	6,083,741	7/04/00	Hart <i>et al.</i>	435	320.1	11/17/95
	A40	6,113,946	9/05/00	Szoka, Jr. <i>et al.</i>	424	486	6/06/95
	A41	6,251,866	6/26/01	Prakash <i>et al.</i>	514	17	8/04/98
	A42	6,262,107	7/17/01	Li <i>et al.</i>	514	449	7/01/99
	A43	5,517,993	5/21/96	Unger and Wu	128	653.4	6/07/95

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1 ✓	WO 95/28966	11/02/95	PCT			
	B2 ✓	WO 97/33552	9/18/97	PCT			
	B3 ✓	WO 99/39748	8/12/99	PCT			
	B4 ✓	WO 99/49901	10/07/99	PCT			
	B5 ✓	WO 99/61512	12/02/99	PCT			
	B6 ✓	WO 00/53233	9/14/00	PCT			
	B7 ✓	WO 00/61788	10/19/00	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C147 ✓	Anderson <i>et al.</i> , "Radiometal-labeled agents (non-technetium) for diagnostic imaging," <i>Chem. Rev.</i> , 99:2219-2234, 1999.
	C148 ✓	Antony, "Folate receptors," <i>Ann. Rev.</i> , 16:501-521, 1996.

25387887.1

EXAMINER:

DATE CONSIDERED: 6/15/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E. Edmund Kim

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

June 21, 2000

1616

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 2

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C149 ✓	Aoi <i>et al.</i> , "Globular carbohydrate macromolecule 'sugar balls' 3. 'radical-growth polymerization' of sugar-substituted α -amino acid N-carboxyanhydrides (glycoNCAs) with a dendritic initiator," <i>Tetrahedron, Elsevier Science Publishers</i> , 53(45):15415-15427, 1997.
	✓C150	Bajorin <i>et al.</i> , <i>Proc. Annu. Meet. Am. Soc. Clin. Oncol.</i> , 7:250, A967, 1988.
	C151 ✓	Baselga <i>et al.</i> , "Phase I studies of anti-epidermal growth factor receptor cheimeric antibody C225 alone and in combination with cisplatin," <i>J. Clinical Oncology</i> , 18(4):904-914, 2000.
	C152 ✓	Baselga <i>et al.</i> , "Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/new overexpressing human breast cancer xenografts," <i>Cancer Research</i> , 58:2825-2831, 1998.
	C153 ✓	Benns <i>et al.</i> , "Tailoring new gene delivery designs for specific targets," <i>Journal of Drug Targeting</i> , 8(1), Database Medline on STN International, Accession No. 2000222278, 2 pages, 2000.
	✓C154	Blackenberg <i>et al.</i> , "Apoptosis: the importance of nuclear medicine," <i>Nucl. Med. Comm.</i> , 21:241-250, 2000.
	✓C155	Blackenberg <i>et al.</i> , "In vivo detection and imaging of phosphatidylserine expression during programmed cell death," <i>Proc. Natl. Acad. Sci., USA</i> , 95:6349-6354, 1998.
	✓C156	Blair <i>et al.</i> , "Linkage of cytotoxin agents to immunoglobulins," <i>Journal of Immunological Methods</i> , 59:129-143, 1983..
	✓C157	Block, "Poly(g-benzyl-L-glutamate) and other glutamic acid containing polymers," Gordon and Breach Science Publishers, New York, 11-31, 1983.
	✓C158	Bohdiewicz <i>et al.</i> , "Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging," <i>J. Nuclear Medicine Technology</i> , 26(3):155-163, 1998.
	✓C159	Brechbiel <i>et al.</i> , "Synthesis of 1 (P-isothiocyanatobenzyl) derivatives of DTPA and EDTA: antibody labeling and tumor-imaging studies," <i>Inorg. Chem.</i> , 25:2772-2781, 1986.
	✓C160	Brogi <i>et al.</i> , "Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression," <i>J. Clin. Invest.</i> , 97(2):469-476, 1996.
	✓C161	Brox <i>et al.</i> , "Designing peptide-based scaffolds as drug delivery vehicles," <i>Science</i> , 78(1-3):115-123, 2002.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E. Edmund Kim

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

June 21, 2000

1616

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 2

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
10	✓ C162	Budihardjo <i>et al.</i> , "Biochemical pathways of caspase activation during apoptosis," <i>Annu. Rev. Cell Dev. Biol.</i> , 15:269-290, 1999.
	✓ C163	Burgen, "Targets of drug action," <i>Ann. Rev. Pharmacol. Toxicol.</i> , 40:1-16, 2000.
	✓ C164	Chapman <i>et al.</i> , "Therapeutic antibody fragments with prolonged in vivo half-lives," <i>Nature Biotech.</i> , 17:780-783, 1999.
	✓ C165	Collier <i>et al.</i> , "Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT," <i>Radiology</i> , 185:179-186, 1992.
	✓ C166	Culver <i>et al.</i> , "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," <i>Science</i> , 256:1550-1552, 1992.
	✓ C167	Deguchi <i>et al.</i> , "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker," <i>Bioconjugate Chem.</i> , 10:32-37, 1999.
	✓ C168	DeNardo <i>et al.</i> , "Pharmacokinetics of chimeric L6 conjugated to indium 111- and yttrium-90-DOTA-peptide in tumor-bearing mice," <i>J. Nuclear Medicine</i> , 36:829-836, 1995.
	✓ C169	DeNardo <i>et al.</i> , "Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer," <i>Anticancer Research</i> , 17(3B):1735-1744, 1997.
	✓ C170	Deutsch <i>et al.</i> , "Synthesis of congeners and prodrugs, water-soluble prodrugs of taxol with potent antitumor activity," <i>J. Med. Chem.</i> , 32:788-792, 1989.
	✓ C171	Divgi <i>et al.</i> , "Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma," <i>J. National Cancer Institute</i> , 83(2):97-104, 1991.
	✓ C172	Drobnik <i>et al.</i> , "Soluble synthetic polymers in biological systems," <i>Adv. Polym. Sci.</i> , 57:1-50, 1984.
	✓ C173	Dunn <i>et al.</i> , "Receptor-mediated endocytosis of epidermal growth factor by hepatocytes in the perfused rat liver: ligand and receptor dynamics," <i>J. Cell Biol.</i> , 98:2148-2159, 1984.
	✓ C174	Eary <i>et al.</i> , "Radiochemistry of halogenated antibodies," <i>Antibodies in Radiodiagnosis and Therapy</i> , Boca Ratan, Florida, CPC Press, 83-100, 1988.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E.
Edmund Kim

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

June 21, 2000

1616

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 2

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✓	C175	Eiseman <i>et al.</i> , "Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice," <i>Cancer Chemother. Pharmacol.</i> , 34:465-471, 1994.
✓	C176	Ennis <i>et al.</i> , "Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells," <i>Mol. Endocrinology</i> , 3(11):1830-1838, 1989.
✓	C177	Ethier, "Growth factor synthesis and human breast cancer progression," <i>J. Natl. Cancer Inst.</i> , 87(13):964-973, 1995.
✓	C178	Fan <i>et al.</i> , "Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts," <i>Cancer Research</i> , 53:4637-4642, 1993.
✓	C179	Fan <i>et al.</i> , "Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies," <i>Cancer Research</i> , 53:4322-4328, 1993.
✓	C180	Fang <i>et al.</i> , "Involvement of p21 Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells," <i>Anticancer Research</i> , 20(1A):103-112, 2000.
✓	C181	Fidler <i>et al.</i> , "The biology of cancer invasion and metastasis," <i>Adv. Cancer Res.</i> , 28:149-250, 1987.
✓	C182	Foa <i>et al.</i> , "Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity," <i>J. Clin. Lab. Res.</i> , 24:6-14, 1994.
✓	C183	Frankel <i>et al.</i> , "Targeted toxins," <i>Clin. Cancer Res.</i> , 6:326-334, 2000.
✓	C184	Fuertges <i>et al.</i> , "The clinical efficacy of poly(ethylene glycol)-modified proteins," <i>J. Controlled Release</i> , 11:139-148, 1990.
✓	C185	Fuller <i>et al.</i> , "A procedure for the facile synthesis of amino-acid N-carboxyanhydride," <i>Biopolymers</i> , 15:1869, 1976.
✓	C186	Gabizon, "Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes," <i>Cancer Research</i> , 52:891-896, 1992.
✓	C187	Garipey <i>et al.</i> , "Vectorial delivery of macromolecules into cells using peptide-based vehicles," <i>Trends in Biotechnology</i> , 19(1):21-28, 2001.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E. Edmund Kim

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✓	C188	Girard, "Mechanisms by which carbohydrates regulate expression genes for glycolytic and lipogenic enzymes," <i>Ann. Rev. Nutr.</i> , 17:325-352, 1997.
✓	C189	Goldenberg <i>et al.</i> , "Imaging of human tumor xenografts with and indim-111-labeled anti-epidermal growth factor receptor monoclonal antibody," <i>J. National Cancer Institute</i> , 81:1616-1625, 1989.
✓	C190	Goldenberg, "Monoclonal antibodies in cancer detection and therapy," <i>Am. J. Med.</i> , 94:297-312, 1993.
✓	C191	Goldspeil, "Pharmaceutical issues: preparation, administration, stability, and compatibility owtth other medications," <i>Ann. Pharcother.</i> , 28:S23-S26, 1994.
✓	C192	Gonda, "Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 6(4):273-313, 1990.
✓	C193	Greenfield <i>et al.</i> , "In vitro evaluation of immunoconjugates prepared by linking mitomycin C to monoclonal antibodies via polyglutamic acid carriers," <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 2(3):201-216, 1989.
✓	C194	Greenwald <i>et al.</i> , "Drug delivery systems: water soluble tazol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness," <i>J. Med. Chem.</i> , 39:424-431, 1996.
✓	C195	Halpern <i>et al.</i> , "Stability, characterization, and kinetics of In-labeled monoclonal antitumor antibodies in normal animals and nude mouse human tumor models," <i>Cancer Research</i> , 43:5347-5355, 1983.
✓	C196	Hermanson, "Amine detection reagents," <i>Bioconjugate Techniques</i> , San Diego, Academic Press, 112-114, 1996.
✓	C197	Hermanson, "Ellman's assay for the determination of sulfhydryls," <i>Bioconjugate Techniques</i> , Sand Diego, Academic Press, 88-90, 1996.
✓	C198	Hnatowich <i>et al.</i> , "Radioactive labeling of antibody: a simple and efficient method," <i>Science</i> , 220:613-615, 1983.
✓	C199	Hoes <i>et al.</i> , "Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin," <i>J. Controlled Release</i> , 2:205-213, 1985.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E. Edmund Kim

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
20	C200 ✓	Holmes <i>et al.</i> , "Current status of clinical trials with paclitaxel and docetaxel, taxane anticancer agents: basic science and current status," <i>American Chemical Society</i> , Washington, DC, 31-57, 1995.
	C201 ✓	Hudecz <i>et al.</i> , "Influence of carrier on biodistribution and in vitro cytotoxicity of methotexate-branched polypeptide conjugates," <i>Bioconjugate Chemistry</i> , American Chemical Society, 4(1):25-33, 1993.
	C202 ✓	Inoue <i>et al.</i> , "Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma," <i>Clinical Cancer Res.</i> , 6:4874, 4884, 2000.
	C203 ✓	Irie <i>et al.</i> , "Regression of cutaneous metastatic melanoma by intralosomal injection with human monoclonal antibody to ganglioside GD2," <i>Proc. Natl. Acad. Sci., USA</i> , 83:8694-8698, 1986.
	C204 ✓	Jeppesen <i>et al.</i> , "Impact of polymer tether length on multiple ligand-receptor bond formation," <i>Science</i> , 293:465-468, 2001.
	C205 ✓	Jurisson <i>et al.</i> , "Potential technetium small molecule radiopharmaceuticals," <i>Chem. Rev.</i> , 99:2205-2218, 1999.
	C206 ✓	Kato and Sugiyama, "Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 14(3):287-331, 1997.
	C207 ✓	Kato <i>et al.</i> , "A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid- α -fetoprotein antibody-daunomycin conjugate," <i>J. Med. Chem.</i> , 27:1602-1607, 1984.
	C208 ✓	Kitamura <i>et al.</i> , "Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy," <i>Cancer Research</i> , 51:4310-4315, 1991.
	C209 ✓	Klok <i>et al.</i> , "Star-shaped fluorescent polypeptides," <i>Journal of Polymer Science</i> , 39(10):1572-1582, 2001.
	C210 ✓	Kopecek <i>et al.</i> , "Targetable water-soluble polymeric anticancer drugs: achievements and unsolved problems," <i>Proc. Intern. Symp. Conol. Rel. Bioact. Mater.</i> , 20:190-191, 1993.
	C211 ✓	Kopecek <i>et al.</i> , "Targetable polymeric prodrugs," <i>J. Control. Release</i> , 6:315-327, 1987.
	C212 ✓	Kopecek, "The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery," <i>Journal of Controlled Release</i> , 11:279-290, 1990.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E. Edmund Kim

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

Group:

June 21, 2000

1616

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 2

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<input checked="" type="checkbox"/>	C213	Lamki, "Radioimmunosciintigraphy of cancer: problems, pitfalls, and prospects," <i>Nuclear Medicine Annual 1990</i> , New York, Raven Press Ltd., 113-150, 1990.
<input checked="" type="checkbox"/>	C214	Larson <i>et al.</i> , "Overview of clinical radioimmunodetection of human tumors," <i>Cancer</i> , 73(supp):832-835, 1994.
<input checked="" type="checkbox"/>	C215	Li <i>et al.</i> , "Antitumor activity of poly (L-glutamic acid)-paclitaxel on syngeneic and xenograft tumors," <i>Clinical Cancer Res.</i> , 5:891-897, 1999.
<input checked="" type="checkbox"/>	C216	Li <i>et al.</i> , "Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate," <i>Cancer Res.</i> , 58:2404-2409, 1998.
<input checked="" type="checkbox"/>	C217	Li <i>et al.</i> , "Poly(L-glutamic acid)-anticancer drug conjugates," <i>Advanced Drug Delivery Rev.</i> , 54:695-713, 2002.
<input checked="" type="checkbox"/>	C218	Li <i>et al.</i> , "Synthesis and evaluation of water-soluble polyethylene glycol paclitaxel conjugate as a paclitaxel prodrug," <i>Anticancer Drugs</i> , 7(5):642-648, 1996.
<input checked="" type="checkbox"/>	C219	Li <i>et al.</i> , "Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates," <i>Bioconjugate Chem.</i> , 4:275-283, 1993.
<input checked="" type="checkbox"/>	C220	Liu <i>et al.</i> , "99mTc-labeled small peptides as diagnostic radiopharmaceuticals," <i>Chem. Rev.</i> , 99:2235-2268, 1999.
<input checked="" type="checkbox"/>	C221	Liu <i>et al.</i> , "Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals," <i>Bioconjugate Chemistry</i> , 12:7-34, 2001.
<input checked="" type="checkbox"/>	C222	Liu <i>et al.</i> , "Induction of apoptosis and activation of the capase cascade by anti-EGF receptor monoclonal antibodies in DiFI human colon cancer cells do not involve the C-jun N-terminal kinase activity," <i>British Journal of Cancer</i> , 82(12):1991-1999, 2000.
<input checked="" type="checkbox"/>	C223	Lu <i>et al.</i> , "Polymerizable fab' antibody fragments for targeting of anticancer drugs," <i>Nat. Biotech.</i> , 17:1101-1104, 1999.
<input checked="" type="checkbox"/>	C224	Maeda <i>et al.</i> , "Tumorotropic and lymphotropic principles of macromolecular drugs," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 6(3):193-210, 1989.
<input checked="" type="checkbox"/>	C225	Maeda, "SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy," <i>Adv. Drug Delivery Rev.</i> , 6(2):181-202, 1991.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664	Serial No. 09/599,152
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants David Yang, Chun-Wei Liu, Dong-Fang Yu and E. Edmund Kim	
		Filing Date: June 21, 2000	Group: 1616
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 2	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✓	C226	Mann <i>et al.</i> , "Molecular amplifiers: synthesis and functionalization of a poly(aminopropyl dextran bearing a uniquely reactive terminus for univalent attachment to biomolecules," <i>Bioconjugate Chemistry</i> , 3:154-159, 1992.
✓	C227	Marti and Risau, "Systematic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors," <i>Proc. Natl. Acad. Sci., USA</i> , 95:15809-15814, 1998.
✓	C228	Masui <i>et al.</i> , "Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies," <i>Cancer Research</i> , 44:1002-1007, 1984.
✓	C229	Mathew <i>et al.</i> , "Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity," <i>J. Med. Chem.</i> , 35:145-151, 1992.
✓	C230	Meares <i>et al.</i> , "Macrocyclic chelates of radiometals for diagnosis and therapy," <i>British J. Cancer</i> , 62:21-26, 1990.
✓	C231	Mendelsohn <i>et al.</i> , "Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking autocrine pathway," <i>Trans. Assoc. Am. Phys.</i> , 100:173-178, 1987.
✓	C232	Mendelsohn, "Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy," <i>Clinical Cancer Research</i> , 3:2703-2707, 1997.
✓	C233	Miltross <i>et al.</i> , "Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel," <i>J. National Cancer Institute</i> , 88(18):1308-1314, 1996.
✓	C234	Mitchell <i>et al.</i> , "Active-specific immunotherapy for melanoma," <i>J. Clin. Oncol.</i> , 8(5):856-869, 1990.
✓	C235	Modjahedi <i>et al.</i> , "The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review)," <i>Int. J. Oncology</i> , 4(2):277-296, 1994.
✓	C236	Morton <i>et al.</i> , "Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine," <i>Ann. Surg.</i> , 216(4):463-482, 1992.
✓	C237	Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay," <i>J. Immunol. Methods</i> , 65:55-63, 1983.
✓	C238	Nicolaou <i>et al.</i> , "Design, synthesis, and biological activity of protaxols," <i>Nature</i> , 364:464-466, 1993.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664	Serial No. 09/599,152
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants David Yang, Chun-Wei Liu, Dong-Fang Yu and E. Edmund Kim	
		Filing Date: June 21, 2000	Group: 1616
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 2	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✓	C239	Oldham <i>et al.</i> , "Comparison of action of paclitaxel and poly (L-glutamic acid)-paclitaxel conjugate in human breast cancer cells," <i>Int. J. Oncol.</i> , 16(1):125-132, 2000.
✓	C240	Omelyanenko <i>et al.</i> , "HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates: influence of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro," <i>J. Drug Targeting</i> , 3:357-373, 1996.
✓	C241	Omelyanenko <i>et al.</i> , "HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates II. Processing in epithelial ovarian carcinoma cells in vitro," <i>International Journal of Cancer</i> , 75(4):600-608, 1998.
✓	C242	Ozanne <i>et al.</i> , "Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas," <i>J. Pathol.</i> , 149:9-14, 1986.
✓	C243	Pedley <i>et al.</i> , "The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody," <i>British J. Cancer</i> , 70:1126-1130, 1994.
✓	C244	Petrak <i>et al.</i> , "Transport of macromolecules across the capillary walls," <i>Adv. Drug Deliv. Review</i> , 3:191-214, 1989.
✓	C245	Phillips-Hughes <i>et al.</i> , "Restenosis: pathophysiology and preventive strategies," <i>JVIR</i> , 7:321-333, 1996.
✓	C246	Pietersz <i>et al.</i> , "Specific in vitro anti-tumor activity of methotrexate-monoconal antibody conjugates prepared using human serum albumin as an intermediary," <i>Immunol. Cell Biol.</i> , 66:43-49, 1988.
✓	C247	Pimm <i>et al.</i> , "Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody II: biodistribution studies in mice with human tumor xenografts," <i>Dur. J. Nucl. Med.</i> , 11:300-304, 1985.
✓	C248	Pimm <i>et al.</i> , "Strategies for labelling branched polypeptides with a poly (L-Lysine) backbone with radioiodines 123I, 125I, 131I) and radiometals (111In, 51Cr) for biodistribution studies and radiopharmaceutical development," <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 36(2):157-172, 1995.
✓	C249	Potamianos <i>et al.</i> , "Radioimmunosintigraphy and radioimmunotherapy in cancer: principles and application," <i>Anticancer Research</i> , 20(2A):925-948, 2000.
✓	C250	Putnam <i>et al.</i> , "Polymer conjugates with anticancer activity," <i>Polymer Science</i> , 122:55-123, 1995.

25387887.1

EXAMINER: *D. Jones*DATE CONSIDERED: *6/15/04*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E.
Edmund Kim

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
209	✓C251	Quadri <i>et al.</i> , "Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates," <i>Quart. J. Nucl. Med.</i> , 42:250-261, 1998.
	✓C252	Ravindranath <i>et al.</i> , "Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA," <i>J. Immunol. Methods</i> , 16(197):51-67, 1996.
	✓C253	Reilly <i>et al.</i> , "A comparison of EGF and Mab 528 labeled within for imaging human breast cancer," <i>J. Nucl. Med.</i> , 41:903-911, 2000.
	✓C254	Remington's Pharmaceutical Sciences, 19 th Ed., Mach Printing Company, 1990, Smith and Rutlage, 1975. <i>(Table of Contents), pp. xv - xvi</i>
	✓C255	Rihova <i>et al.</i> , "Antiproliferative effect of a lectin- and anti-thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse thy-1.2 gene," <i>Bioconjugate Chemistry</i> , 11(5):664-673, 2000.
	✓C256	Rihova, "Receptor-mediated targeted drug or toxin delivery," <i>Adv. Drug Deliv. Rev.</i> , 29:273-289, 1998.
	✓C257	Rosenberg <i>et al.</i> , "Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients," <i>Ann. Surg.</i> , 210(4):474-548, 1989.
	✓C258	Roth <i>et al.</i> , "Gene therapy for cancer: what have the inventors done and where are the inventors going?" <i>J. Natl. Can. Inst.</i> , 89(1):21-39, 1997.
	✓C259	Rowinsky <i>et al.</i> , "Paclitaxel (taxol)," <i>New England Journal of Medicine</i> , 332:1004-1014, 1995.
	✓C260	Rowinsky <i>et al.</i> , "Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting," <i>J. Clin. Oncol.</i> , 11(10):2010-2020, 1993.
	✓C261	Rowland <i>et al.</i> , "Suppression of tumor growth in mice by drug-antibody conjugate using a novel approach to linkage," <i>Nature</i> , 255:487-488, 1975.
	✓C262	Sabbantini <i>et al.</i> , "Early findings in a phase I study of PG-Paclitaxel (CT2103 in recurrent ovarian or primary peritoneal cancer," <i>Proc. AACR-NCI-EORTC Int. Conference on Molecule Targets and Cancer Therapeutics</i> , Abs, 470:96, 2001.
209	✓C263	Semenza, "Regulation of mammalian O ₂ homeostasis by hypoxia-inducible factor 1," <i>Ann. Rev. Cell Dev. Biol.</i> , 15:551-578, 1999.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E.
Edmund Kim

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✓	C264	Serruys <i>et al.</i> , "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," <i>New England J. Medicine</i> , 331(8):489-495, 1994.
✓	C265	Seymour <i>et al.</i> , "Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumor-targeted drug delivery," <i>Select. Cancer Therapeut.</i> , 7(2):59-73, 1991.
✓	C266	Shih <i>et al.</i> , "Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier," <i>Cancer Res.</i> , 54:4192-4198, 1991.
✓	C267	Shimada <i>et al.</i> , "Biodistribution of liposomes containing synthetic galactose-terminated diacylglycerol-poly(ethylen glycol)s," <i>Biochimica et Biophysica Acta</i> , 1326:329-341, 1997.
✓	C268	Sudimack <i>et al.</i> , "Targeted delivery via folate receptor," <i>Adv. Drug Deliv. Rev.</i> , 41:147-162, 2000.
✓	C269	Surwit <i>et al.</i> , "Clinical assessment of In-CYT-103 immunoscintigraphy in ovarian cancer," <i>Gynecol. Oncol.</i> , 48:285-292, 1993.
✓	C270	Takamizawa <i>et al.</i> , "Differential apoptosis gene expression in pediatric tumors of the kidney," <i>J. Ped. Surg.</i> , 35(2):390-395, 2000.
✓	C271	Takashina <i>et al.</i> , "Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol," <i>Jpn. J. Cancer Res.</i> , 82:1145-1150, 1991.
✓	C272	Tam, "Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system," <i>Proc. Natl. Acad. Sci., USA</i> , 85:5409-5413, 1988.
✓	C273	Tomalia <i>et al.</i> , "Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology and flexibility from atoms to macroscopic matter," <i>Angew. Chem. Int. Ed. Engl.</i> , 29:138-175, 1990.
✓	C274	Torchilin <i>et al.</i> , "Chelating polymer modified monoclonal antibodies for radioimmunodiagnostics and radioimmunotherapy," <i>J. Controlled Release</i> , 24:111-118, 1993.
✓	C275	Van Heeswijk <i>et al.</i> , "The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin Part 1," <i>J. Controlled Release</i> , 1:301-315, 1985.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E. Edmund Kim

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C276 ✓	Vega <i>et al.</i> , "Targeting adriamycin to EGF receptors by site-specific conjugation of monoclonal antibody to poly(L-glutamic acid)," Division of Deagnostic Imaging and Departmetn of Experimental Therapeutics, U.T. M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA.
	C277 ✓	Vyas <i>et al.</i> , "Phosphatase-activated prodrugs of paclitaxel," Taxane Anticancer Agents: Basic Science and Current Status, <i>American Chemical Society</i> , Washington, DC, 124-137, 1995.
	C278 ✓	Wahl <i>et al.</i> , "Loss of normal p53 function confers sensation to taxol by increasing g2/m arrest and apoptosis," <i>Nat. Med.</i> , 2(1):72-79, 1996.
	C279 ✓	Wahl, "Monoclonal antibodies in nucear medicine," <i>Nuclear Medicine Annual 1992</i> , New York, Raven Press Ltd., 91-103, 1992.
	C280 ✓	Weiss <i>et al.</i> , "Hypersensitivity reaction from taxol," <i>J. Clin. Oncol.</i> , 8(7):1263-1268, 1990.
	C281 ✓	Wells <i>et al.</i> , "Glycosylation of nucleocytoplasmic proteins: signal transduction and)-glcNAc," <i>Science</i> , 291:2376-2378, 2001.
	C282 ✓	Wen <i>et al.</i> , "Conjugation with 111In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225," <i>J. Nuclear Medicine</i> , 42(10):1530-1537, 2001.
	C283 ✓	Wen <i>et al.</i> , "Improved radiolabeling of PEFylated protein: PEGylated annexin V for noninvasive imaging of tumor apoptosis," <i>Bioconjugate Chemistry</i> , 2002.
	C284 ✓	Wen <i>et al.</i> , "Poly(ethylene glucol) conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains," <i>Bioconjugate Chem.</i> , 12:545-553, 2001.
	C285 ✓	Wu <i>et al.</i> , "Apoptosis induced by and anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin," <i>J. Clin. Invest.</i> , 95:1897-1905, 1995.
	C286 ✓	Yasui <i>et al.</i> , "Expression of epidermal growth factor receptor in human gastric and colonic carcinomas," <i>Cancer Res.</i> , 48:137-141, 1995.
	C287 ✓	Yokoyama <i>et al.</i> , "Polymer micelles as novel drug carrier: adriamycin-conjugated poly(ethylen glycol)-poly(aspartic acid) block copolymer," <i>J. Controlled Release</i> , 11:269-278, 1990.
	C288 ✓	Yokoyama <i>et al.</i> , "Preparation of micelle-formin polymer-drug conjugates," <i>Bioconjugate Chem.</i> , 3:295-301, 1992.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicants

David Yang, Chun-Wei Liu, Dong-Fang Yu and E.
Edmund Kim

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	✓ C289	Young <i>et al.</i> , "Influence of immunoglobulin heavy and light-chain expression on B-cell differentiation," <i>Genes Develop.</i> , 8:1043-1057, 1994.
	✓ C290	Becker <i>et al.</i> , "Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody," <i>American Journal of Pathology</i> , 155(6):1803-1809.
	✓ C291	Garayoa <i>et al.</i> , "Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis," <i>Molecular Endocrinology</i> , 14:848-862, 2000.
	✓ C292	Hibi <i>et al.</i> , "PGP9.5 as a candidate tumor marker for non-small-cell lung cancer," <i>American Journal of Pathology</i> , 155(3):711-715, 1999.
	✓ C293	Kanazawa <i>et al.</i> , "19F NMR of 2-deoxy-2-fluoro-D-glucose for tumor diagnosis in mice. An NDP-bound hexose analog as a new NMR target for imaging," <i>NMR in Biomed.</i> , 10:35-41, 1997.
	✓ C294	Yamori <i>et al.</i> , "Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel," <i>Cancer Res.</i> , 59:4042-4049, 1999.

25387887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)